Neuroprotective and anti-inflammatory effects of the adenosine A2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease

Synapse

Volumn 65, Issue 3, 2011, Pages 181-188

  Frau, Lucia ^a   Borsini, Franco ^b   Wardas, Jadwiga ^c   Khairnar, Amit S ^a   Schintu, Nicoletta ^a   Morelli, Micaela ^a,d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b TAU   (Italy)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d CNR   (Italy)

Author keywords

CD11b; Dopamine; GFAP; Neuron degeneration; Striatum; Substantia nigra compacta; TH

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; ST 1535; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CAUDATE NUCLEUS; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; GLIOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUTAMEN; STEREOMETRY; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 78650654063     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20833     Document Type: Article

References (56)

1. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN. 2003. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61: 293-296.
2. Barcia C, Sánchez Bahillo A, Fernández-Villalba E, Bautista V, Poza Y, Poza M, Fernández-Barreiro A, Hirsch EC, Herrero MT. 2004. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46: 402-409.
3. Belcastro V, Tozzi A, Tantucci M, Costa C, Di Filippo M, Autuori A, Picconi B, Siliquini S, Luchetti E, Borsini F, Calabresi P. 2009. A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol 217: 231-234.
4. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. 2009. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 111: 1478-1489.
5. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli NJr, Schwarzschild MA. 2001. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21: RC143.
6. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ. 1996. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18: 152-160.
7. Galluzzo M, Pintor A, Pezzola A, Grieco R, Borsini F, Popoli P. 2008. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535. Eur J Pharmacol 579: 149-152.
8. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. 1999. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52: 1673-1677.
9. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-013 Study Group. 2008. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 23: 2177-2185.
10. Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann Neurol 44(3 Suppl 1 ): S115-S120.
11. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. 2003. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 214-228.
12. Huang QY, Wei C, Yu L, Coelho JE, Shen HY, Kalda A, Linden J, Chen JF. 2006. Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. J Neurosci 44: 11371-11378.
13. Hunot S, Hirsch EC. 2003. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53: S49-S58.
14. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. 2002. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80: 262-270.
15. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. 2000. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162: 321-327.
16. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 46: 598-605.
17. Lewitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM, 6002-US-005 Study Group. 2008. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63: 295-302.
18. Marchi M, Raiteri L, Risso F, Vallarino A, Bonfanti A, Monopoli A, Ongini E, Raiteri M. 2002. Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol 136: 434-440.
19. Marcoli M, Raiteri L, Bonfanti A, Monopoli A, Ongini E, Raiteri M, Maura G. 2003. Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45: 201-210.
20. McGeer PL, McGeer EG. 2008. Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
21. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
22. McGeer PL, Yasojima K, McGeer EG. 2001. Inflammation in Parkinson's disease. Adv Neurol 86: 83-89.
23. Melani A, Pantoni L, Bordoni F, Gianfriddo M, Bianchi L, Vannucchi MG, Bertorelli R, Monopoli A, Pedata F. 2003. The selective A(2A) receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 959: 243-250.
24. Meredith GE, Dervan AG, Totterdell S. 2005. Activated microglia persist in the substantia nigra of a chronic MPTP mouse model of Parkinson's disease. In: Bolam JP, Ingham CA, Magill P, editors. The basal ganglia VIII. Singapore: Springer Science. p 341-347.
25. Minetti P, Tinti MO, Carminati P, Castorina M, Di Cesare MA, Di Serio S, Gallo G, Ghirardi O, Giorni F, Giorgi L, Piersanti G, Bartoccini F, Tarzia G. 2005. 2-n-Butyl-9-methyl-8-[1, 2, 3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem 48: 6887-6896.
26. Morelli M. 2003. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Exp Neurol 184: 20-23.
27. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G. 1996. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 19: 13-18.
28. Ongini E, Fredholm BB. 1996. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 17: 364-372.
29. Paxinos G, Franklin KBJ. 2001. The mouse brain in stereotaxic coordinates, 2nd ed. San Diego, CA: Academic Press.
30. Pierri M, Vaudano E, Sager T, Englund U. 2005. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48: 517-524.
31. Pinna A, Pontis S, Borsini F, Morelli M. 2007. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 61: 606-614.
32. Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M. 2010. A new ethyladenine antagonist of adenosine A(2A) receptors: Behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58: 613-623.
33. Popoli P, Betto P, Reggio R, Ricciarello G. 1995. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 287: 215-217.
34. Rebola N, Canas PM, Oliveira CR, Cunha RA. 2005. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience 132: 893-903.
35. Ridet JL, Malhotra SK, Privat A, Gage FH. 1997. Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci 20: 570-577.
36. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. 2007. Neuroinflammation in Alzheimer's disease and Parkinson's disease: Are microglia pathogenic in either disorder? Int Rev Neurobiol 82: 235-246.
37. Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P. 2006. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 546: 82-87.
38. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. 1998. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401: 163-186.
39. Ross GW, Abbott RD, Petrovitch H, White LR, Tanner CM. 2000. Relationship between caffeine intake and parkinson disease. JAMA 284: 1378-1379.
40. Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J. 2005. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95: 919-929.
41. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S. 2007. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83: 277-292.
42. Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR. 2009a. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 16: 127-39.
43. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR. 2009b. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 29: 954-963.
44. Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli NJr, Chen JF. 2003. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 61(11 Suppl 6 ): S55-S61.
45. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. 2006. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29: 647-654.
46. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. 2008. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70: 2233-2240. Erratum in:Neurology71:953.
47. Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P, Ghirardi O, Carminati P. 2006. ST1535: A preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol 9: 575-584.
48. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. 1999. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 59: 355-396.
49. Tansey MG, McCoy MK, Frank-Cannon TC. 2007. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208: 1-25.
50. Teismann P, Ferger B. 2001. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39: 167-174.
51. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, Vila M, Jackson-Lewis V, Przedborski S. 2003. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18: 121-129.
52. Tozzi A, Tscherter A, Belcastro V, Tantucci M, Costa C, Picconi B, Centonze D, Calabresi P, Borsini F. 2007. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 53: 783-789.
53. Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M. 2007. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats. Eur J Pharmacol 566: 94-102.
54. Wardas J. 2002. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 54: 313-326.
55. Whitton PS. 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150: 963-976.
56. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.